Protocol Ledger

NCT03258554 · Phase II/III · COMPLETED

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

Interventional Phase II/III clinical trial protocol NCT03258554 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-04-03 Enrollment: 196 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03258554
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)196 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03258554
Protocol FieldVerified Registry Value
NCT IdentifierNCT03258554
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusCOMPLETED
Registered Enrollment196 participants (ACTUAL)
Registered Start Date2018-04-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI